SELECTED ORAL COMMUNICATION SESSION, SESSION 34: EARLY PREGNANCY LOSS PROGNOSIS AND TREATMENT, Tuesday 5 July 2011 10:00 - 11:30

Autor: M. Entwisle, N.P. Polyzos, Z. Abediasl, Marcelo Zugaib, M. Palep-singh, B. Ermini, P. Haentjens, R. Horiuchi, Ai-Wei Tang, S. Miyaji, J Drury, R.P.V. Francisco, M. Moini, Edmond Edi-Osagie, Aisaku Fukuda, P. Devroey, D. Stoop, G. Verheyen, Y. Morimoto, Zarko Alfirevic, Siobhan Quenby, K. Adam, Feroza Dawood, G. Bhima, Mark A. Turner, Fábio Roberto Cabar, Eleonora Jansen, J Topping, A. Haruki, M. De Vos, Roy G. Farquharson, Pedro Paulo Pereira, K. O’toole
Rok vydání: 2011
Předmět:
Zdroj: Human Reproduction. 26:i48-i50
ISSN: 1460-2350
0268-1161
DOI: 10.1093/humrep/26.s1.34
Popis: Introduction: Multiple trials of immunotherapy for reproductive failure have failed to demonstrate significant benefit. A reason for this may be the lack of a test that selects which women will benefit from treatment. High density of uterine naturak killer (uNK) cells has been associated with recurrent miscarriage (RM) and prednisolone was shown to reduce this uNK cell density. Hence we carried out a double blind randomised placebo controlled trial of prednisolone versus placebo in early pregnancy for women with RM and increased uNK cell density. The aim of this pilot trial was to assess the feasibility of recruitment, integrity of trial procedures and potential efficacy for future power calculations.
Databáze: OpenAIRE